Trial Profile
A PHASE 2A, MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE PILOT EFFICACY, SAFETY, AND PHARMACOKINETICS OF 2 OINTMENT FORMULATIONS OF CP-690,550 IN SUBJECTS WITH MILD TO MODERATE CHRONIC PLAQUE PSORIASIS
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications Plaque psoriasis
- Focus Biomarker; Therapeutic Use
- 05 Mar 2013 Pruritis and patient satisfaction results presented at the 71st Annual Meeting of the American Academy of Dermatology.
- 05 Mar 2013 Primary endpoint 'Target-Plaque-Severity-Score' has been met for formulation one versus vehicle one as presented at the 71st Annual Meeting of the American Academy of Dermatology.
- 05 Mar 2013 Results presented at the 71st Annual Meeting of the American Academy of Dermatology.